The description of a cell-free soluble anti-tumour factor by Carswell et al. in 1975 (Proc Natl Acad Sci USA, 72: 3666–3670) was followed by a long series of experimental and clinical investigations into the role of cell-free mediators in cancer immunotherapy. These investigations included research on the effects of macrophage-derived eicosanoids (cyclooxygenase and lipoxygenase derivatives of arachidonic acid) and of monokines such as tumour necrosis factor-α, interleukin-1 and granulocyte–monocyte–macrophage-colony stimulating factor) and of lymphocyte products: interleukins and interferons. The investigations yielded information on the effects of various factors on macrophage and T-cell activation in vitro, determination of direct anti-tumour properties on animal and human tumour cells in vitro and on therapeutic effectiveness in tumour-bearing individuals either alone or in combination with other therapeutic factors and their production by tumour cells. During recent years much effort has been dedicated towards the use of the tumour cells transfected with cytokine genes in the preparation of cancer vaccines. Cyclooxygenase products (prostaglandins) were usually assumed to inhibit expression of anti-tumour activity by macrophages and an increase in their production in cancer patients was considered as a poor prognostic index. Lipoxygenase (leukotrienes) products were assumed to exhibit anti-tumour activity and to induce production of IL-1 by macrophages. Interleukins 2, 4, 6, 7, 12 and the interferons were extensively tested for their therapeutic effectiveness in experimental tumour models and in cancer clinical trials. The general conclusion on the use of cell-free mediators for cancer immunotherapy is that much still has to be done in order to assure effective and reproducible therapeutic effectiveness for routine use in the treatment of human neoplasia.

**Key words:** Cancer immunotherapy, Cytokines, Eicosanoids, Interferons, Interleukins, Leukotrienes, Prostaglandins

**Cancer immunotherapy: potential involvement of mediators**

S. Ben-Efraim

Department of Human Microbiology, Sackler Faculty of Medicine Tel-Aviv University, Tel-Aviv 69978, Israel
Fax: (+972) 3 6409160
Tel: (+972) 3 6416682

**Introduction**

The field of cancer immunotherapy began approximately 100 years ago with rather ‘naïve’ attempts to use anti-tumour antibodies raised in various animals for treatment in human sarcoma patients. At around the same time Coley was probably the first (1891, cited in reference 3) to suggest that cell-free filtrates of bacteria might possess anti-tumour activities. Macrophages are known to produce and secrete derivatives of arachidonic acid and cytokines (such as TNF-α and Interleukin-1 (IL-1)), T and B cells produced and released a long series of interleukins; both macrophage and T and B-cell products are involved in the interaction between the immune system and tumour cells in a number of ways: direct anti-tumour activity, activation of immunocompetent cells in vivo and/or in vitro, and changes in their production in vivo in tumour-bearing hosts. Finally, it was shown that tumour cells themselves might secrete some of the above mentioned products and develop a means to resist the anti-tumour activity of various biologically active products.
The data accumulated on the activities of macrophages and T cell products against tumour cells helped to devise certain immunotherapeutic protocols first in experimental animal tumour systems and afterwards in human neoplasia. The immunotherapeutic protocols were based on either treatment with cell-free products alone or in combination with other treatments. They also helped in devising ways to activate in vitro immuno-competent cells for therapeutic uses in vivo.

The aim of this review is to discuss the potential involvement of cell-free mediators in cancer immunotherapy. On reviewing their anti-tumour activities it should be mentioned that some of these mediators are also involved in inflammatory processes and that their production is closely interrelated.

Eicosanoids and Cancer

Cyclooxygenase (prostaglandins) and lipoxygenase products have been used in experimental tumour systems and are involved in human neoplasia.

Prostaglandins

It has generally been assumed that prostaglandins (especially PGE₂) inhibit anti-tumour activity of macrophages. Thus a PGE₂ inhibitor, indomethacin, enhanced the macrophage cytostatic activity in vitro against MOPC315 murine plasmacytoma cells. Indomethacin stimulation of macrophage cytostasis was inhibited by PGE₂ and this enhancement of anti-tumour activity was also reported in vivo against Ehrlich murine tumour cells. The effect of endogenous and exogenous prostaglandins on macrophage functions was described: culture conditions that caused increased PGE₂ production by activated macrophages resulted in an inhibition of their tumoricidal activity whereas production of high levels of PGE₂ by resident and elicited macrophages was associated with an increase in their tumoricidal activity. In another work, it was reported that a subcutaneous injection of polyacrylamide beads in mice induced a population of immature macrophages which became fully cytotoxic to syngeneic P815 plasmacytoma when stimulated in vitro by LPS. Blocking of PGE synthesis by indomethacin prevented the effect of LPS and addition of PGE₂ did not reverse the indomethacin effect but inhibited the macrophage-mediated cytostatic activity. Suppression of macrophage-mediated tumour cytotoxicity was correlated with an increase in secretion of prostaglandin from the macrophages of breast cancer patients. Elevated prostaglandin production in human breast cancer was considered a marker of high metastatic potential for neoplastic cells, the increase in PG production occurred early in the course of breast cancer and decreased later in the course of tumour development. It seems that PGE₂ production by human monocytes is by a subset of cells other than the cells which produce IL-1. It should also be mentioned that cancer cells also produce PGE₂ and in this context it was reported that the amount of PGE₂ released by cancer cells which metastasized into the liver of tumour-bearing rats was higher than that of cells metastasizing into the kidney. An increase in prostaglandin levels in cancer patients was also reported: of plasma prostaglandin F levels in cases of tumours of the female genital tract and of plasma 6-oxo-prostaglandin F₁α in cases of gynaecological tumours.

On the assumption that prostaglandins can suppress the development and expression of effector cells, clinical studies were initiated to determine the effect of piroxicam (a prostaglandin antagonist) in patients with recurrent unresectable squamous cell carcinoma or lymphoepithelial carcinoma of the head and neck. Although some improvement in immune reactivity was noted, more studies to correlate the improvement in immune reactivity with therapeutic effectiveness of either prostaglandin antagonists alone or in combination with other treatments are needed. A paradoxical effect of indomethacin on lymphokine-activated killer (LAK) activity in cancer patients was described: indomethacin enhanced LAK activity in patients with no distant metastases but depressed LAK activity in patients with such metastases. Apparently, these effects of indomethacin are not related to the PGE inhibiting property of this compound. Increased synthesis of prostaglandin by macrophages from breast cancer patients was assumed to inhibit macrophage mediated cytotoxicity.

Leukotrienes

Leukotrienes (lipoxygenase pathway of arachidonic acid) are usually considered to enhance the potential of the immune response. Thus, leukotriene and indomethacin enhance additively the macrophage anti-tumour cytostatic function. Leukotriene B4 (LTB₄) was reported to augment human monocyte cytotoxic activity and enhance monocyte production of hydrogen peroxide, IL-1 and TNF. 5-Lipoxygenase activation was also described to facilitate
an IL-1 transduction signal. Augmentation by leukotrienes of IL-1 production by human monocytes was also described in other reports. Lipooxygenase specifically inhibited indomethacin stimulation of anti-tumour macrophage cytostasis and reversed macrophage cytostasis, induced by the calcium ionophore A23187, towards P815 tumour cells in vitro. Leukotriene C4 was reported to be an essential 5-lipoxygenase intermediate in A23187-induced macrophage cytostatic activity against P815 tumour cells. Products of the lipooxygenase pathway were involved in human natural killer cell cytotoxicity.

**Cytokines**

Immunocompetent cells reported to produce and secrete cytokines involved in the reaction of the organism to tumour cells were macrophages, T and B cells.

**Macrophage-derived cytokines**

Biologically active products described as being involved in the interaction with tumour cells were tumour necrosis factor-α (TNF-α) interleukin-1 (IL-1) and granulocyte–macrophage colony stimulating factor (GM-CSF).

**TNF-α**

The first description of TNF-α as a macrophage product was made by Carswell et al. Since then, several reviews have appeared which have been concerned with the characterization and properties of this cytokine. The mechanism and activity spectrum of TNF-α has been the topic of several investigations: it was reported that exposure of human cervical carcinoma cells to Concanavalin A (ConA) increased the total number of binding sites for rTNF-α but blocked the transduction of the signal for the cytotoxic response. MethA sarcoma cells were found to be sensitive in vitro to human tumour recombinant TNF-α and expressed low numbers of TNF-α receptors. TNF-α (unlike INF-γ or IL-1α) induced regression of subcutaneous MethA implants. It was assumed that the primary lesion induced by TNF-α is vascular and the mechanism(s) involved in generation of specific cell-mediated anti-tumour immunity induced by the TNF-α treatment was not clear. It was claimed that there are multiple pathways leading to resistance to TNF-α induced tumour cell cytotoxicity, among them production of transforming growth factors by tumour cells and amplified expression of certain oncogenes. Apparently, viable activated monocytes produce other lytic factors in addition to TNF-α and IL-1 because TNF-α and IL-1 associated with plasma membranes of activated human monocytes lyse only monokine-sensitive tumour cells whereas viable activated monocytes lyse both monokine-sensitive and monokine-resistant tumour cells.

The killing of tumour cells by TNF-α was assumed to involve internalization of this ligand in the target cells. The anti-tumour effect of TNF-α and of Interferon-γ against MmB16 murine melanoma was potentiated by macrophage colony-stimulating factor. The anti-tumour activity of recombinant human TNF-SAM1 was enhanced by connecting the TNF compound to thymosin β4. TNFα acted synergistically with IL-1 in inhibiting the growth of A375 cells. An experimental study carried out in nude mice showed that intratumoral injection of an adenoviral vector containing radiation inducible DNA sequence of the Egr-1 promoter linked to a cDNA encoding TNF-α (Ad.Egr-TNF) enhanced the tumorcidal action of ionizing radiation in a human epidermoid carcinoma xenograft. By another experimental approach it was shown that murine tumour cells transduced with the gene for TNF-α, regressed unlike non-transduced tumour cells after an initial phase of tumour growth.

The results in vitro and in vivo from experimental tumour models which indicated the anti-tumour activity of TNF-α, prompted initiation of clinical trials devised to determine the therapeutic effectiveness of TNF-α in human neoplasia. Intravenous injection of TNF-α in 18 cancer patients led to some clinical improvement in three lymphoma patients. Recombinant TNF-α was given in combination with TNF-γ in phase I trials in 36 patients with solid tumours. Side-effects such as fatigue, fever and chills occurred: in one patient with melanoma there was a mixed response and in one patient with mesothelioma there was transient clearance of ascites from malignant cells. Disappointing results were reported in a phase II study of recombinant human TNF-α in 127 cancer patients. The conclusion of the authors was that: “rhuTNFα does not appear to have significant anti-tumour activity”. A similar conclusion was made in a phase II trial of rTNF-α in 22 patients with adenocarcinoma of the pancreas: “No objective responses were observed”. A phase II study of recombinant TNF-α was also performed in a group of 26 renal cell carcinoma patients. The conclusion was: “rTNF given as described, has only modest anti-tumour activity in renal carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease”. In a phase I study including 16
evaluable patients with various types of metastatic cancer, there was evidence for anti-tumour effect in two patients. The property of TNF-α as an immunomodulator was reported; pretreatment of monocytes with IFN-α, IFN-γ, IL-1 or TNF-α resulted in enhanced human monocyte toxicity.

Interleukin-1

The production, characterization and properties of IL-1 have been summarized in several reviews. It was stated that IL-1 is a key mediator of host response to microbial invasion and that it acts as a true hormone produced during infection and inflammation. Human recombinant IL-1 (hrIL-1) induced proliferative responses of T cells in the presence of sub-optimal concentrations of mitogen and doubled the response to higher concentrations. Human recombinant IL-1 induced release of IL-2 by T cells and acted as a potent inflammatory agent by inducing dermal fibroblast PGE₂ production in vitro and of fever in rabbits and mice. The overall conclusion from these data was that IL-1 possesses both immunological and inflammatory properties. Human interleukin-1 acted as a cytoidal factor for several tumour cell lines and promoted human monocyte-mediated tumour cytotoxicity. Human monocytes stimulated with pneumococcal cell surface components produced IL-1 but not TNF, thus showing independence of production of the two cytokines. As mentioned already, IL-1 acted synergistically with TNF-α against tumour cells. IL-1α enhanced carboplatinum anti-tumour activity against human ovarian cells in vitro and in vivo. In an in vitro study with human melanoma cell lines it was shown that tumour cells which secrete IL-1 exhibited increased adhesion to endothelial cells.

Granulocyte–macrophage colony stimulating factor (GM-CSF)

The effect of intravenous and intraperitoneal administration of GM-CSF was examined in a phase I trial of 13 cancer patients refractory to standard chemotherapy. Administration of GM-CSF was well tolerated but no data were provided on clinical improvement. In another study, it was reported that administration of GM-CSF in 24 patients with solid tumours enhanced monocyte cytotoxicity against a human colon carcinoma line but no data are given on the effect on clinical course of the disease.

The partial and somehow disappointing results obtained in clinical trials with TNF-α may be due to several factors:

- TNF-α can be administered only in small amounts because higher amounts are toxic and induce severe side effects.
- TNF-α is a relatively small molecule and as such, is rapidly cleared after injection.
- It is possible that some human cells are resistant to TNF-α or develop mechanism(s) of defence against the anti-tumour activity of TNF-α.
- Anti-tumour activity in vivo requires more than one anti-tumour factor.
- TNF-α in vivo does not occur sufficient concentration in its contact with tumour cells.

In view of the results obtained in clinical trials with TNF-α, experiments were undertaken to use activated human macrophages or activated human peripheral blood for therapy. It was assumed that macrophages can act indiscriminately against immunogenic or non-immunogenic tumours, and that they might release monokines continuously in vivo (in addition to TNF-α and/or IL-1) which would be active against the tumour cells. It should be mentioned in this context that activated macrophages might release anti-tumour cytostatic products unrelated to IL-1, TNF-α and INF-α/β. Results of in vitro experiments showed that peritoneal human macrophages obtained from renal patients on continuous ambulatory peritoneal dialysis (CAPD) can be activated in vitro by LPS to express anti-tumour activity and as such they acted in vivo against a human tumour implanted subcutaneously in nude mice. Similarly, human peripheral blood cells from cancer patients, activated in vitro by IFN-γ and LPS, reacted against a human tumour growing in nude mice. These results prompted clinical trials with autologous human peripheral blood monocytes activated in vitro and reinjected in to the cancer patients. The therapeutic effectiveness of this procedure was limited and probably more clinical trials are required in order to improve conditions for therapy with activated macrophages.

Lymphocyte-derived Interleukins

Interleukin-2

Interleukin-2 (IL-2) is one of the main products of T cells and was extensively studied in the context of its anti-tumour activity. IL-2 was reported to increase human natural killer (NK) cell activity in vitro and this activity was partially reduced by monocytes due to PGE₂ production. Murine lymphocytes cultured in
the presence of IL-2 lysed syngeneic murine tumour cells. The lytic activity was attributed to the occurrence of lymphocyte activated killer (LAK) cells Thy-1 + Lyt-1-2+. The described effects of IL-2 in enhancing anti-tumour activity promoted a series of clinical trials devised to determine the therapeutic effects of IL-2 in cancer patients. It was found that of 106 patients with metastatic cancer receiving LAK cells plus IL-2, eight had complete responses, 15 had partial responses and ten had minor responses. The same group of researchers reported that autologous tumour infiltrating lymphocytes (TIL), cultured in the presence of IL-2, lysed melanoma tumour cells. Melanoma-specific cytolytic tumour lymphocytes derived from TIL grown in the presence of IL-2, and injected together with IL-2, induced tumour rejection in vivo possibly by reacting against the gp100 epitope. A phase I trial in a total of 31 evaluable patients with metastatic cancer of the breast, gastric cancer, colorectal cancer, melanoma, non-small cell lung cancer, osteosarcoma or renal cancer, received a combined treatment of IL-2, followed by TNF-α and indomethacin, two partial responses were seen (in breast and renal cancer). In another clinical trial, 16 patients with advanced renal cell cancer (stage IV) received a combined treatment of cyclophosphamide, INF-α and IL-2. Two patients had a partial response, two had a minor response and three patients achieved stable disease. The effect of IL2 with or without LAK cells was assayed in another group of 71 patients with advanced renal cell carcinoma. A low level of anti-tumour response was detected and the addition of LAK cells did not improve the response. IL-2 administration was found to prolong survival of some metastatic renal cell carcinoma patients with no or moderate HLA-II expression and/or no or moderate macrophage presence in the primary tumour, but was not effective in patients with both high HLA-II and high macrophage expression. Some potential uses of IL-2 treatment have been described: IL2 and IL-7 augmented the cytolytic activity and the anti-tumour killing spectrum of αCD3-induced activated killer cells, and such cells were suggested for immunotherapy of non-immunogenic tumours. Cytotoxicity of induced LAK cells against human leukaemia was augmented in the presence of either IFN-α, IFN-γ or TNF-α in cultures, and as such they might be more effective in treating human leukaemia. Adoptive therapy of established pulmonary metastases with LAK cells and recombinant IL-2 has been reported. Adoptive therapy with highly enriched NK cells was assumed to have a potential use in leukaemia. It should be also mentioned that LAK cells are apparently not a unique cell type but a function of various types of cells. Finally, one of the problems of IL-2 therapy is the toxicity of the compound: in this context, it was suggested that the oxygen free-radical scavenger, dimethylthiourea, ameliorates pulmonary permeability and vascular leak syndrome associated with multiple-dose IL-2 therapy without inhibiting IL-2 induced anti-tumour cytotoxicity. On the other hand, the tumour-associated antigen 90K and the soluble IL-2 receptor were associated with poor prognosis in human ovarian cancer. Another way of promoting the anti-tumour activity of IL-2 was by gene transfer into tumour cells. The use of a human renal carcinoma line transfected with IL-2 and/or INF-α gene has been suggested for the preparation of live cancer vaccines. Combined treatment with granulocyte colony stimulating factor and IL-2 increased the survival time of nude mice bearing human ovarian cancer cells.

**Interleukin-4**

Interleukin-4 was first described as B-cell stimulatory factor. IL-4 was reported to inhibit tumour growth of syngeneic mammary adenocarcinoma, plasmacytoma, and renal carcinoma by using cytokine gene transfer into the murine tumours. Repeated injections of small amounts of IL-4 around the tumour draining nodes of mice resulted in growth inhibition of poorly immunogenic and non-immunogenic tumours (cited in reference 94). Transfection of IL-4 into tumour cells induced release of this cytokine and it was effective, in vivo, against a wide range of tumour cells implanted in nude mice. Similarly, treatment of established murine renal cancer by tumour cells engineered to secrete IL-4, induced specific T-cell dependent systemic immunity against the non-transfected tumour. To my knowledge, IL-4 therapy has not yet been tested in human neoplasia.

**Interleukin-6 (INF-β2)**

Interleukin-6 is induced in T cells by antigen stimulation. Purified human recombinant (rIL-6) mediated substantial reduction in the number of tumours. Recombinant human IL-6 produced in *Escherichia coli* inhibited the growth of human breast carcinoma and leukaemia/lymphoma cell lines in vitro. Anti IL-6 receptor antibody prevented muscle atrophy in Colon-26 adenocarcinoma bearing mice, thus suggesting that this antibody could be a potential agent against muscle atrophy in cancer cachexia.
6 gene transfer into murine syngeneic tumours inhibited growth of lung carcinoma\(^9\) and sarcoma.\(^9\) IL-6 gene transfected into Lewis Lung Carcinoma tumour cells suppressed the malignant phenotype and was effective against parental metastatic cells.\(^9\) Mice rejecting murine fibrosarcoma cells, transduced with retroviral vectors containing the murine IL-6 gene and secreting IL-6, exhibited a later resistance to challenge with wild tumour cells.\(^9\) Aquisition of the ability to synthesize endogenous IL-6 markedly accelerated the growth of weakly tumorigenic rat urothelial cells, but did not induce a tumorigenic phenotype in non-tumorigenic cells.\(^9\)

**Interleukin-7 (B/T maturation factor)**

Murine plasmacytoma cells transfected with the IL-7 gene produced IL-7 \(\text{in vivo}\) and were completely rejected in syngeneic mice by a T-cell dependent process.\(^9\)

**Interleukin-12**

IL-12 has received considerable attention during recent years as a strong anti-tumour agent: IL-12 was reported to react \(\text{in vivo}\) against B16F10 tumour-bearing mice and its anti-tumour effect was inhibited by anti-IFN\(\gamma\) antibody.\(^9\) IL-12-transfected fibroblast cells admixed with the murine melanoma, BL6, showed that local IL-12 expression suppressed tumour growth and promoted development of specific anti-tumour immunity.\(^9\) IL-12 engineered dendritic cells were effective \(\text{in vivo}\) against murine tumour cells.\(^9\) In another report, it was shown that anti IFN\(\gamma\) antibody blocked IL-12-mediated tumour regression in mice.\(^9\) In view of the results obtained from IL-12 therapy against murine tumours, clinical trials were initiated to determine the effect of IL-12 in human cancer. Phase I clinical trials of IL-12 gene therapy were done by direct injection of tumours with genetically engineered autologous fibroblasts.\(^9\) Out of 13 cancer patients (six breast, five melanoma, and two head and neck), significant reduction in tumour size was observed in three patients with melanoma and one with head and neck cancer.\(^9\)

**Interferon-\(\alpha\)**

A clinical trial was done in renal cancer and melanoma patients by treatment with IFN-\(\alpha\).\(^9\) Of 12 melanoma patients, four patients showed a partial response whereas eight patients progressed.\(^9\) In the case of 35 patients with advanced renal cancer, an increase in immune response potential was observed.\(^9\) The conclusion was that more studies are required to determine the therapeutic effectiveness of IFN-\(\alpha\).\(^9\) A human renal carcinoma line transfected with the IL-2 and/or the IFN-\(\alpha\) gene was suggested for use in preparation of live cancer vaccines.\(^9\)

**Interferon-\(\gamma\) (IFN-\(\gamma\))**

IFN-\(\gamma\) was first described as an antiviral agent and was among the first cytokines assayed for therapeutic effectiveness in human neoplasia. In one of the first clinical trials done in Hodgkin’s disease patients it was reported that treatment with IFN-\(\gamma\) led to an extension of the disease-free survival time.\(^9\) Complete or partial remission in multiple myeloma by IFN-\(\gamma\) treatment was also reported.\(^9\) Remissions induced by IFN-\(\gamma\) were also reported in patients with lymphocytic lymphoma,\(^9\) in cases of metastatic breast cancer,\(^9\) non-Hodgkin’s lymphoma,\(^9\) and multiple myeloma.\(^9\) However, in another study in a group of non-small cell lung cancer patients, IFN-\(\gamma\) treatment did not induce tumour regression.\(^9\) A phase I trial on the effect of IFN-\(\gamma\) treatment was conducted in six patients with lung cancer,\(^9\) systemic side effects such as transient fever, nausea, headaches and flu-like symptoms were noted,\(^9\) but no data on therapeutic effect were given.\(^9\) In a recent \(\text{in vitro}\) study it was reported that human carcinoma cell lines cultured with IFN-\(\gamma\) expressed more CD80 and CD86 costimulatory molecules and that this increase in expression was inhibited by IL-10.\(^9\) Transfer of the IFN-\(\gamma\) gene into murine neuroblastoma,\(^9\) fibrosarcoma,\(^9\) adenocarcinoma,\(^9\) colon carcinoma,\(^9\) and lung carcinoma cell lines induced tumour inhibition in syngeneic mice. Human peripheral blood monocytes collected from cancer patients were activated \(\text{in vitro}\) to express anti-tumour activity in the presence of IFN-\(\gamma\) and LPS.\(^9\)

**Anti-tumour effects vs other functions of cytokines**

Some facts which should be considered in the context of the anti-tumour activity of cytokines are discussed below.

**Relationship with inflammatory functions**

Macrophage-derived cytokines such as TNF-\(\alpha\) and IL-1 are also major inflammatory mediators.\(^5,27,28,37,56,57\) Human peritoneal macrophages from CAPD patients collected during infectious peritonitis are ‘primed’ to produce and secrete more TNF-\(\alpha\) and IL-1 when cultured in the presence of LPS.\(^121,122\) These data indicate
that inflammation and cancer are interrelated events.

**Interactions in cytokine production**

Production and release of various eicosanoids and cytokines are closely interrelated. For example: production of IL-1, TNF-α and IL-6 by human mononuclear cells was induced by stimulatory agents such as LPS.\(^{36}\) LPS-induced TNF-α production is inhibited by PGE\(_2\).\(^{123}\) Endotoxin, TNF-α and IL-1 induce IL-6 production in vitro;\(^{24}\) production of IL-1 and TNF-α was induced in human blood mononuclear cells by LPS, whereas IL6 suppressed the induction of IL-1β and TNF-α by LPS or PHA.\(^{125}\)

**Production of eicosanoids and cytokines by tumour cells**

Production of eicosanoids and cytokines by tumour cells may have an influence on the effect of these products on tumour development: tumour cells might produce PGE\(_2\).\(^{126}\) The response of murine tumours to indomethacin therapy was directly related to their ability to produce prostaglandin;\(^{127}\) tumours from cachectic mice produced both TNF-α and IL-1α in vivo;\(^{128}\) a myeloma human cell line produced both TNF-α and IL-6;\(^{129}\) leukaemic cells from patients with acute myeloid leukaemia produced both IL-6 and IL-1.\(^{130}\) These are a few examples; the relationship between the ability of tumour cells to produce eicosanoids or cytokines and development of cancer is not yet clear.

**Production of eicosanoids and cytokines in the tumour-bearing host**

During tumour growth in rats cyclooxygenase or thromboxane synthase was inhibited whereas C5 and C12-lipoxygenases of the alveolar macrophages were activated.\(^{131}\) Macrophages derived from tumour-bearing animals suppressed activation of T cells, of NK cells, of LAK cells and of generation of tumoricidal activity in normal syngeneic splenic macrophages in cultures stimulated by LPS.\(^{132}\) The secretion of IL-1, TNF-α but not of IL-6 was impaired in alveolar macrophages collected from tumour-bearing mice.\(^{133}\) A decrease in production of IL-1 was also reported in peritoneal macrophages collected from sarcoma-bearing mice.\(^{134}\) Production of IL-1 and TNF-α by tumour associated mononuclear monocytes from cancer patients was examined and showed that production IL-1 was suppressed whereas production of TNF-α was not affected.\(^{35}\) LPS induced TNF-α production was impaired in macrophages from breast cancer patients,\(^{36}\) but increased in patients with malignant brain tumours.\(^{137}\) An example of correlation between production of TNF-α and PGE\(_2\) by peripheral blood monocytes was seen in patients with bladder cancer: these patients had either higher TNF-α production or higher PGE\(_2\) production.\(^{138}\)

**Cell-free mediators as cancer therapeutic agents**

In vitro activation of cells for immunotherapy

Activation of autologous human peripheral blood monocytes by culture in the presence of LPS and IFN-γ was assayed with the aim of inducing anti-tumour cytotoxic activity in the treated monocytes and to use such activated cells for immunotherapy.\(^{68,69}\) Clinical trials reported limited success.\(^{68,69}\) Induction of LAK cells, and later of activated tumour infiltrating lymphocytes (TIL) by culturing in the presence of IL-2 was also suggested in a series of reports.\(^{71–74}\) Clinical trials were carried out in groups of cancer patients; the results obtained indicated some therapeutic benefit in melanoma and renal carcinoma with approximately 10% clinical improvement in patients treated with both IL-2 and LAK cells.\(^{72}\)

Direct administration of cytokines in cancer patients

As previously mentioned the results of treatment with TNF-α were disappointing; injection of IL-2 with or without LAK cells was problematic due to the toxicity of the agent; the effect of IL-2 in patients with squamous cell carcinoma of the head and neck was limited to temporary regression of the tumours.\(^{139}\) Another approach suggested was to counteract the activity of PGE\(_2\) by using a PGE inhibitor; while some improvement in immunological functions was observed no data are yet available on the therapeutic effectiveness of this treatment.\(^{21}\)

Transfection of tumour cells with cytokine genes

This approach has been extensively investigated during recent years, firstly in experimental tumour models and later in clinical trials. The transfected tumours released the appropriate cytokine in vitro and in some cases induced T-cell mediated specific anti-tumour immunity. Partial success was observed in terms of tumour regression and clinical improvement.\(^{140–142}\) Productive transfer of the IL-2 gene was shown for
therapeutically effective in tumour cells transfected with cytokine genes. It is assumed that transfected tumour cells are more immunogenic and as such they induce a T cell mediated response against the wild type non-transfected tumour. They might also secrete cytokines in vivo which react against the tumour cells.

Marked progress has been made during recent years on the interaction between macrophages and lymphocyte products and tumour cells, and on their possible role in immunotherapy against cancer. However, many more clinical trials are required before these agents can be used in routine therapy of human neoplasia.

Concluding Remarks

The ‘golden’ era on the role of cytokines in the fight against cancer started with the description by Carswell in 1975 of tumour necrosis factor. Since then, various aspects of the interaction between eicosanoids, macrophage and lymphocyte cytokines and tumour state have been described and investigated. The various topics of investigation included:

- direct effects in vitro and in vivo of eicosanoids and cytokines on tumour cells in experimental and clinical trials;
- activation of monocytes, macrophages and lymphocytes in vitro by cytokines for use in autologous cancer patients;
- effect of tumour state in experimental systems and human neoplasia on the production and release of eicosanoids and cytokines;
- therapeutic effectiveness of combined treatment with activated immunocompetent cells and cytokines;
- role of secretion of eicosanoids and cytokines by tumour cells in the interaction between the tumour cells and the tumour-bearing host;
- therapeutic effectiveness of tumour cells transfected with cytokine genes. It is assumed that transfected tumour cells are more immunogenic and as such they induce a T cell mediated response against the wild type non-

References

1. Hericourt J, Richet Ch. De la Sérothérapie dans le traitement du cancer. CR Hebd Acad Sci (Paris) 1985; 120: 567–569.
2. Hericourt J, Richet Ch. Traitement d’un cas de sarcome par la sérothérapie. CR Hebd Acad Sci (Paris) 1985; 120: 948–950.
3. Ruff MR, Gifford GE. Tumour Necrosis Factor In: Pick E ed. Lymphokinins, New York: Academic Press, Inc., 1981: 2: 235–272.
4. Ophir R, Ben-Efraim S, Bonta IL. Leukotriene D4 and indomethacin enhance additively the macrophage cytotactic activity towards MOPC-315 tumour cells. Int J Tiss React 1987; 9: 189–194.
5. Bonta IL, Ben-Efraim S. Interactions between inflammatory mediators in expression of antitumor cytotactic activity of macrophages. Immunology Lett 1990; 25: 295–302.
6. Elliott GR, Tak C, Bonta IL. Prostaglandin E2 enhances, and leukotriene C4 inhibits, interleukin-1 inhibition of WEHI-3B cell growth. Cancer Immunol Immunother 1989; 28: 74–80.
7. Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumour-bearing mice and prevents tumour metastasis. Cell Immunol 1986; 99: 108–118.
8. Lala PK, Parhar RS. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin-2: characterization of killer cells generated in situ. Cancer Res 1988; 48: 1072–1079.
9. Lala PK, Parhar RS, Singh P, Lala PK. Cure of murine Ehrlich ascites tumours with chronic oral indomethacin therapy combined with intraperitoneal administration of LAK cells and IL-2. Cancer Letters 1990; 51: 27–35.
10. Lala PK, Elkahash M, Kerbel RS, Parhar RS. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characterization of killer cells generated in situ. Intern Immunol 1990; 2: 1149–1158.
11. Snider ME, Fertel RH, Zwillling BS. Prostaglandin regulation of macrophage function: endogenous and exogenous prostaglandins. Cell Immunol 1982; 74: 234–242.
12. Draper JC, Petit JE. Development of antitumor activity in EPS-stimulated mouse granuloma macrophages. Regulation by eicosanoids. Inflammation 1986; 10: 201–209.
13. Cameron DJ, Rittenbury M, Mjøs J. Ability of cancer patient's macrophages to kill autologous tumor targets. Effects of prostaglandin inhibitors on cytotoxicity. Cancer 1984; 53: 2053–2057.
14. Cameron DJ, Stromberg BV. The ability of macrophages from head and neck cancer patients to kill tumor cells. Cancer 1984; 54: 2403–2408.
15. Rolland PH, Martin PM, Jacquier JM, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. JNCI 1980; 64: 1061–1070.
16. Khamsari N, Ghou YK, Fudenberg H. Human monocytes heterogeneity: interleukin-1 and prostaglandin E2 production by separate subsets. Eur J Immunol 1985; 15: 48–51.
17. Nakazawa I, Otuski K, Watanabe M, Tsuuranji SA. Difference in prostaglandin E2 synthesis between cancer cell metastasizing into liver and kidney. Prostaglandins Leukotrienes Med 1985; 17: 265–266.
18. Sanders RR, Lee WH, Koh L, Brennecke A, Jones WR. Plasma prostaglandin F levels and malignant tumor stage of the female genital tract. Br J Obstet Gynaecol 1980; 87: 139–142.
19. Alam M, Jogee M, Mcgregor WG, Dowell TW, Elder MGE, Matt L. Peripheral plasma immunoreactive 6x0-prostaglandin F3a and gynecological tumors. Br J Cancer 1982; 45: 384–389.
20. Beau DP, Harris JE, Rubenstein M. Relationship of arachidonic acid metabolism to indomethacin sensitive immunoregulatory function and PGE sensitivity in peripheral blood mononuclear cells of disseminated solid tumor cancer patients. J Immunopharmacol 1984; 6: 227–236.
21. Beaus DP, Taylor SG IV, Harris JE. Modulation of immunity in cancer patients by prostaglandin antagonists. In: Medich MS ed. Immunology
Advances in Prostaglandins, Thrombocytes and Leukotrienes Research to Cancer II. Progress in Clinical and Biological Research

Smith MR, Munger WE, Kung HF, Takacs L, Durum SK. Direct evidence for an intracellular role for tumor necrosis factor.

Agents Actions 1988; 21: 187–200.

Lasek W, Wankowicz A, Kuc K. 1986; 21: 4023–4026.

Hilten van JA, Elliott GR, Bonta IL. Specific lipoxigenase inhibition reverses macrophage cytostasis towards P815 tumor cells in vitro induced by the calcium ionophore A23187. Prostagl Leuk Ess Fatty Acids 1988; 34: 187–192.

Rola-Pleszczynski M, Stankova J. Cytokine regulation by PGE2. Immunol Lett 1990; 34: 289–290.

Rossi P, Lindgren JA, Kullman C, Jondal M. Productsofthelipoxygenasepathwayinhumannaturalkillercellcytotoxicity.

Infect Immun 1987; 53: 2407–2411.

Intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor. J Immunother 1994; 17: 217–223.

Burrows FJ, Haskard DO, Hirt IR, et al. Influence of tumor-derived Interleukin-1 on melanoma-endothelial cell interactions in vitro. Cancer Res 1991; 51: 4648–4777.

Selby P, Hobbs S, Viner C, et al. Tumour necrosis factor in man: clinical and biological observations. Brit J Cancer 1987; 56: 802–808.

Smith JW, Ueba WJ, Clark JW, et al. Phase I evaluation of recombinant Tumor Necrosis Factor given in combination with recombinant Interferon-gamma. J Immunother 1991; 10: 353–362.

Hersch EM, Mecklenburg DA, McGuffey RJ, et al. Phase II trials of recombinant human Tumor Necrosis Factor alpha in patients with malignant disease: a summary of the southwest oncology group experience. J Immunother 1991; 10: 426–431.

Skilling J, Wierbicki R, Eihenauer E, et al. A Phase II study of recombinant Tumor Necrosis Factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 1992; 11: 67–70.

Bick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant Tumor Necrosis Factor in cancer patients. Cancer Res 1991; 51: 4075–4082.

Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 1986; 323: 86–88.

Dinarello CA. The interleukin-1 system: A comparison to tumor necrosis factor. Immunol Lett 1987; 16: 227–231.

Dinarello CA, Cannon GJ, Mer JW, et al. Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1987; 80: 1743–1759.

Oozaki K, Mutsukawa K, Kleineyer ES, Sato T, Oppenheim J. Role of interleukin-1 in promoting human monocyte-mediated tumor cytotoxicity. Int J Immunopharmacol 1993; 15: 315–318.

Oozaki K, Mutsukawa K, Aggarwal BB, Oppenheim J. Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 5962–5968.

Riesenfelder O, Wolpe S, Garcia-Bustos JE, Hoffmann MK, Toumanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun 1989; 57: 1890–1893.

Wang Z, Lee KB, Reed E, Sinha BK. Sensitization by Interleukin-1α of carboplatinum anti-tumor activity against human ovarian (NIHOV-CAR-3) carcinoma cells in vitro and in vivo. Int J Cancer 1996; 67: 585–587.

Burrows FJ, Haskard DO, Hirt IR, et al. Influence of tumor-derived Interleukin-1 on melanoma-endothelial cell interactions in vitro. Cancer Res 1991; 51: 4648–4777.

Tabor GC, Gathrowe, Breitling V, et al. Phase I trial of intravenous and intraperitoneal administration of granulocyte–macrophage colony-stimulating factors. J Immunother 1994; 15: 59–66.

Chachoua A, Oratz R, Hoogmoed R, et al. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother 1994; 15: 217–224.

Lepoirre M, Boubid H, Lemaire G, Petit JP. Cytotoxic product(s) released by activated macrophages, unrelated to Interleukin-1, Tumor Necrosis factor α, and Interferon-α. Cell Immunol 1988; 115: 27–38.

Ben-Efraim S, Tack C, Romijn K, Fieren MWA, Bonta I. Therapy with human macrophages against a human tumor implanted in nude mice. Med Oncol Tumor Pharmacother 1994; 11: 7–12.
with allogeneic melanoma cell tumor lines. Fine specificity MAK-T
melanoma antigen recognition. J Immunol 1955; 154: 762–771.
74. Kawakami Y, Ilyahu S, Jennings G, et al. Recognition of multiple epistites in both melanoma and melanoma tumor-initiating
T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961–3968.
75. Negrin MS, Pourreau GN, Palmer PA, et al. Phase I trial of recombinant interleukin-2 followed by recombinant Tumor Necrosis Factor in patients with metastatic cancer. J Immunol 1992; 10: 93–102.
76. Wersall JP, Masucci G, Hjelm AL, et al. Low dose cyclophosphamide, allogeneic-interferon and continuous infusion of interleukin-2 in advanced renal cell carcinoma. Med Oncol Tumor Pharmacother 1993; 10: 239–298.
77. Ting CC, Wang J, Yang Y. Interleukin-2 and interleukin-7 augment the cytotoxic activity and expand the antitumor-killing spectrum of effector T cells. / Immunol 1995; 154: 287–298.
78. Buscema J, Miescher B, Cerny T, et al. Increased vascular permeability induced by prolonged interleukin-2 administration is attenuated by the oxygen-free radical scavenger dimethylthiourea. Cancer Immunol Immunother 1996; 43: 283–292.
79. Teichmann JV, Ludwig WD, Thiel E. Cytotoxicity of Interleukin 2 induced lymphokine activated killer cells (LAK) cells against human leukemia and melanoma and induction of killer activity on interleukin and tumor necrosis factor. Leukemia Res 1992; 16: 287–298.
80. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established metastases with LAK cells and recombinant interleukin-2. Science 1989; 245: 1217–1224.
81. Russell SJ, Eccles S, Hemmig G, et al. Increased tumori-genicity of a transplantable rat sarcoma following transfer and expression of an IL-2 DNA. / Exp Med 1991; 174: 266–277.
82. Gansbacher B, Zier K, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1995; 92: 5086–901.
83. Bellegurin A, Tso CL, Sakata T, et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha genes: implications for live cancer vaccines. JNCI 1995; 87: 207–216.
84. Kikuchi Y, Imai Iszumi E, Katoaka Y, et al. Effects of granulocyte colony-stimulating factor and Interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells. Cancer Immunol Immunother 1996; 43: 284–292.
85. Tepper RI, Pattengale PK, Leder P. Marine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503–512.
86. Golumbeck PT, Lazenby AJ, Levinsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete Interleukin-4. Science 1993; 261: 1504–1506.
87. Elasser-Belle U, von Kleist S. Cytokines as therapeutic and diagnostic agents. Tumor Biol 1993; 14: 69–94.
88. Mule JJ, McIntosh JK, Jablonis DM, Rosenberger SA. Antitumor activity of recombinant interleukin-2 in mice. J Exp Med 1990; 171: 629–636.
89. Chen L, Mory Y, Zilberstein A, Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interleukin-2. Prog Natl Acad Sci USA 1985; 82: 8037–8041.
90. Fujita J, Tsuina G, Yano M, et al. Anti-interleukin-6 receptor antibody prevents murine lymphoma in colón-26 adenocarcinoma-bearing mice with modulation by foseral and Atp-Biuprotein dependent proteolytic pathways. Int J Cancer 1996; 68: 637–643.
91. Porgador A, Tsehovar E, Katz A, et al. Interleukin 6 gene transfection in Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679–3686.
92. Wille H, Soder AH, et al. Fibrosarcoma cells transduced with the IL6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 1992; 52: 6020–6024.
93. Ochma M, Oyao A. Effect of transfected interleukin-6 in non-tumorigenic and tumorigenic rat urothelial cell lines. Int J Cancer 1996; 68: 616–621.
94. Hock BH, Dorsch M, Daimmanstein T, Blankenstein T. Interleukin 7 induces CD4 + T cell dependent tumor rejection. J Exp Med 1991; 174: 1291–1298.
95. Brunda MJ, Luftser L, Rumennik L, et al. Interleukin-12: Models of a potent antitumor agent. In: Lotze MT, Trinchier G, Myle W, eds. Interleukin-12: Cellular and molecular immunology of an important regulatory cytokine. New York: Ann New York Acad Sci, 1996; 795: 266–274.
96. Tahara H, Zingel I, Storkus WJ, Robbins PD. Lymphoid tissue. Marine models of cancer cytokine gene therapy using Interleukin-12. In: Lotze MT, Trinchier G, Myle W, eds. Interleukin-12: Cellular and molecular immunology of an important regulatory cytokine. New York: Ann New York Acad Sci, 1996; 795: 275–283.
97. Zingel I, Goudere B, Mayordomo JL, Storkus WJ. IL-12 engineered dendritic cells were potent vaccine agents in vivo. In: Lotze MT, Trinchier G, Myle W, eds. Interleukin-12: cellular and molecular immunology of an important regulatory cytokine. New York: Ann New York Acad Sci, 1996; 795: 284–293.
98. Fujinami N, Clark SC, Hamaoka T. Cellular and molecular mechan-isms underlying immunotherapy. In: Lotze MT, Trinchier G, Myle W, ed. Interleukin-12: Cellular and molecular immunology of an important regulatory cytokine. New York: Ann New York Acad Sci, 1996; 795: 294–309.
99. Lotze MT, Trinchier G, Miyake M, et al. Cytokine gene therapy of cancer using Interleukin-12: murine and clinical trials. In: Lotze MT, Trinchier G, Myle W, eds. Interleukin-12: Cellular and molecular immunology of an important regulatory cytokine. New York: Ann New York Acad Sci, 1996; 795: 1067–1074.
100. Zingel I, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with interleukin-12: Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393–1405.
101. Tahara H, Lotze MT. IL-12 therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995; 6: 1067–1074.
102. Tsavaris N, Baxevanis K, Kosmidis P, Papamichael M. The prognostic significance of immune changes in patients with renal cancer melanoma treated with interferon-α. Tumor Biol 1995; 16: 365–373.
103. Strander H. Interferons: Antineoplastic drugs. Blut 1977; 35: 277–288.
104. Melstedt H, Borkholm B, Jontti B, et al. Interferon therapy in myelomastosis. Lancet 1979; I: 245–247.
105. Merigan TC, Sklora K, Breeden JH, et al. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. New Engl J Med 1979; 85: 1499–1453.
106. Gutterman J, Yap Y, Buzdar R, et al. Exogenousexpression of mouse interferon gamma DNA in mouse neuroblastoma CI300 cells results in reduced immunogenicity by augmented antitumor immunity. Proc Natl Acad Sci USA 1988; 86: 9496–9490.
107. Gansbacher B, Bannerre R, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Proc Natl Acad Sci USA 1988; 85: 6020–6024.
108. Watanabe Y, Kuriyabashi K, Myatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma CI300 cells results in reduced immunogenicity by augmented antitumor immunity. Proc Natl Acad Sci USA 1989; 86: 9496–9490.
109. Watanabe Y, Kuriyabashi K, Myatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma CI300 cells results in reduced immunogenicity by augmented antitumor immunity. Proc Natl Acad Sci USA 1989; 86: 9496–9490.
110. Gansbacher B, Bannerre R, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Proc Natl Acad Sci USA 1989; 86: 6020–6024.
macrophages from patients on Continuous Ambulatory Peritoneal Dialysis have an increased capability to release tumour necrosis factor during peritonitis. J Clin Lab Immunol 1993; 34: 1–9.

123. Spengler RN, Spengler MJ, Lincoln P, et al. Dynamics of dibutyryl cyclic AMP and prostaglandin E2 mediated suppression of lipopolysaccharide-induced tumour necrosis alpha gene expression. J Immunol 1989; 57; 2837–2841.

124. Spengler RN, Spengler ML, Lincoln P, et al. Dynamicsofdibutyrylcyclic AMPandprostaglandin E2 mediated suppression of lipopolysaccharide-induced tumour necrosis alpha gene expression. J Clin Lab Immunol 1993; 34: 1 ± 9.23. Spengler RN, Spengler ML, Lincoln P, et al. Dynamicsofdibutyrylcyclic AMPandprostaglandin E2 mediated suppression of lipopolysaccharide-induced tumour necrosis alpha gene expression. J Clin Lab Immunol 1993; 34: 1 ± 9.

125. Skyes J, Maddox IS. Prostaglandin production by experimentaltumorsandeffectsofanalgesic compounds. Nature New Biology 1972; 237: 59 ± 61.

126. Economou JS, Goulphon SD, Anderson TM, et al. Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients. Int J Cancer 1988; 42: 712 ± 714.

127. Zielinski GC, Mueller C, Tyl E, et al. Impaired production of tumor necrosis factor in breast cancer. Cancer 1991; 68: 1944 ± 1948.

128. Barra BP, Rogers JR, Thomasen MJ, et al. Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother 1991; 33: 314 ± 318.

129. Economou JS, Goulphon SD, Anderson TM, et al. Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients. Int J Cancer 1988; 42: 712 ± 714.

130. Zielinski GC, Mueller C, Tyl E, et al. Impaired production of tumor necrosis factor in breast cancer. Cancer 1991; 68: 1944 ± 1948.

131. Barra BP, Rogers JR, Thomasen MJ, et al. Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother 1991; 33: 314 ± 318.

132. Economou JS, Goulphon SD, Anderson TM, et al. Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients. Int J Cancer 1988; 42: 712 ± 714.